Supracondylar Distal Femur Fractures and Abaloparatide
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Supracondylar femur fractures in the geriatric population present a unique challenge to the
orthopaedic surgeon both in terms of fixation, healing, and final extremity axial alignment.
Pulsed dosing of parathyroid hormone derivatives (Forteo) has been shown to increase bone
mass, and several studies in Europe have demonstrated its benefit as an adjuvant for fracture
healing. Abaloparatide represents a new compound which similarly offers great potential for
accelerating fracture healing, especially healing associated with callous formation. This is
a randomized, double blind placebo-controlled trial to compare a group of patients being
treated for supracondylar distal femur fractures who receive abaloparatide (n=38) with a
control group of patients who receive a placebo (n=38).